BranchLab, a Boulder-based startup promising to thread the needle between effective pharmaceutical marketing and patient privacy, has closed a $26 million Series A round led by McKesson Ventures. The May 13 announcement—which included participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures—brings the company's total funding to $35 million since it launched in February 2024.
The deal is a bet on a particular vision: that AI can predict health outcomes and target the right patients without ever touching the protected health information that has become regulatory quicksand. BranchLab's Pathwai platform, according to the company, trains on patient data inside customer-controlled environments, then deploys models using only non-sensitive demographic and media signals. No personal health records. No tracking pixels following patients across the web. Just patterns and predictions, aggregated and anonymized.
Whether that's enough to satisfy regulators, privacy advocates, and pharmaceutical marketers simultaneously remains an open question. But the investor lineup suggests serious players believe it might be.
McKesson Ventures brings distribution heft from one of the country's largest healthcare companies. Sanofi Ventures adds pharmaceutical credibility. FCA Venture Partners, a Nashville firm focused on healthcare, rounds out the group alongside AIX Ventures. "Combining a deep understanding of the patient journey with a future-proofed approach to patient activation," is how Carrie Williams, partner at McKesson Ventures, described the appeal—though the phrase "future-proofed" may be doing some heavy lifting given how quickly both technology and regulation have been moving.
The regulatory landscape that created BranchLab's opportunity has been shifting. The Department of Health and Human Services updated HIPAA guidance on online tracking technologies in 2024, clarifying that even seemingly innocuous web beacons could constitute violations when used on patient portals or telehealth platforms. The FTC, meanwhile, has gone after companies like GoodRx for sharing sensitive health data for advertising purposes, imposing sanctions and setting a precedent that sent ripples through the digital health ecosystem.
Pharmaceutical companies found themselves in an uncomfortable position: they still needed precise audience targeting to reach the right patients for new therapies, but the data practices that had powered that targeting were suddenly fraught with legal risk. Too broad, and marketing dollars get wasted. Too precise, and lawyers start circling.
BranchLab's pitch is that its transformer-based architecture sidesteps the dilemma entirely. The company claims an average improvement of nearly 70% in "commercialization efficacy" across therapeutic areas—though that figure comes from vendor-provided data and doesn't specify the baseline it's measured against. Perhaps more telling: dentsu, the global media network, announced in February that it would integrate Pathwai to transform its proprietary consumer data into healthcare-relevant audience segments. BranchLab also joined the Coalition for Innovative Media Measurement's inaugural startup program, a signal of growing industry acceptance.
At $26 million, the Series A sits comfortably above the $19.6 million median for U.S. first institutional rounds in the first quarter of this year, according to PitchBook-NVCA data. It also comes at a moment when digital health funding has grown more selective—Rock Health reported earlier this year that capital is concentrating into fewer startups, with investors favoring established players or companies with clear paths to profitability.
The competitive landscape is crowded but not yet consolidated. DeepIntent operates a demand-side platform for health media. Veeva Crossix offers audience measurement tools. Komodo Health provides real-world evidence. Swoop, backed by IPG, has built another privacy-respecting audience solution. Each has carved out a slightly different technical or go-to-market angle, and none has achieved dominant market share.
BranchLab's founders bring adtech pedigrees that may prove useful in navigating this terrain. CEO Josh Walsh co-founded AdTheorent, which went public on the NASDAQ in 2021. President Michael Parkes previously served as president and chief revenue officer at VideoAmp, a measurement and optimization platform that raised over $300 million before its own growth trajectory stalled. Whether that experience translates to the more tightly regulated pharmaceutical space is another matter.
Andrew Bouldin, managing partner at FCA Venture Partners, framed the investment around a structural inefficiency he's watched persist for years: "Pharma has spent years investing in data and analytics, but much of it still lives outside of production systems." BranchLab, he suggested, is building the connective tissue to change that—integrating directly into the workflows where pharmaceutical marketers actually make decisions.
The fresh capital will fund enterprise deployments, deeper integrations across the healthcare and media ecosystem, and continued platform development. The company says Pathwai unifies research, marketing, and measurement workflows while activating audiences across media channels with continuous retraining on observed health events. That's a lot of jargon for what amounts to a closed-loop system: predict, target, measure, refine, repeat.
LinkedIn shows approximately 42 listed employees, with offices in New York, Boulder, and San Francisco, according to earlier disclosures. Newark Venture Partners led the seed round in June 2024, and Next Ventures made a strategic investment last September.
For now, BranchLab's hypothesis—that privacy-preserving AI can be both effective and compliant in pharmaceutical marketing—remains exactly that. But with McKesson's name on the cap table and dentsu integrating the technology, the company has bought itself time and credibility to prove it out. In an industry where regulatory missteps can be ruinously expensive, that may be the most valuable currency of all.
